The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Impact of underrepresented populations on clinical outcomes of chemo-immunotherapy for extensive-stage small cell lung cancer: Real-world prospective cohort study.
 
Motohiro Tamiya
Honoraria - Asahi Kasei; AstraZeneca Japan; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Chugai Pharma; Lilly; MSD; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
Consulting or Advisory Role - AstraZeneca; Bayer; Boehringer Ingelheim; Chugai Pharma; Pfizer
 
Daichi Fujimoto
Honoraria - AstraZeneca Japan; Boehringer Ingelheim; Bristol-Myers Squibb Co Ltd; Chugai Pharma; Lilly Japan; MSD; Novartis; Ono Pharmaceutical; Taiho Pharmaceutical
Consulting or Advisory Role - AstraZeneca Japan; Chugai Pharma
Research Funding - AstraZeneca Japan; Boehringer Ingelheim (Inst); Chugai Pharma (Inst)
 
Hiroaki Akamatsu
Honoraria - AstraZeneca Japan; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Lilly Japan; Merck Sharp & Dohme; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
Research Funding - Amgen; Chugai Pharma; Merck Sharp & Dohme
 
Takeshi Morimoto
Consulting or Advisory Role - Novartis; Teijin Pharma
 
Akito Hata
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Lilly; MSD
Speakers' Bureau - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Lilly; Taiho Pharmaceutical
Research Funding - AstraZeneca; AstraZeneca (Inst); Boehringer Ingelheim; Boehringer Ingelheim (Inst); Lilly; Lilly (Inst); MSD; MSD (Inst)
 
Hirotaka Matsumoto
Honoraria - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Lilly; Ono Pharmaceutical; Taiho Pharmaceutical
 
Atsushi Nakamura
Honoraria - AstraZeneca; Chugai Pharma; Kyowa Kirin; Lilly Japan; Novartis; Taiho Pharmaceutical; Thermo Fisher Scientific
 
Yuko Oya
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Lilly
Consulting or Advisory Role - Lilly
 
Hisanori Amimoto
Honoraria - AstraZeneca; Chugai Pharma; Taiho Pharmaceutical
 
Haruko Daga
Honoraria - Chugai/Roche; Taiho Pharmaceutical
Research Funding - AstraZeneca (Inst); Chugai/Roche (Inst); Lilly (Inst)
 
Hideki Ikeda
Honoraria - AstraZeneca Japan; Bristol-Myers Squibb; Chugai Pharma; MSD K.K; Ono Pharmaceutical
 
Shinya Sakata
Honoraria - AstraZeneca; Chugai Pharma
 
Hidekazu Suzuki
Honoraria - AstraZeneca; Bristol-Myers Squibb; Chugai Pharma; Lilly; MSD; Ono Pharmaceutical
 
Satoshi Ikeda
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Lilly; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
Research Funding - AstraZeneca; Chugai Pharma
 
Yuhei Harutani
No Relationships to Disclose
 
Ryota Hiraoka
No Relationships to Disclose
 
Masaaki Yanai
No Relationships to Disclose
 
Yoichiro Hamamoto
No Relationships to Disclose
 
Nobuyuki Yamamoto
Honoraria - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; GlaxoSmithKline; Hisamitsu Pharmaceutical; Janssen; Janssen; Kyowa Kirin International; Lilly Japan; Merck; MSD; Nippon Kayaku; Novartis; Ono Pharmaceutical; Pfizer; Sanofi; Taiho Pharmaceutical; Takeda; Tsumura & Co.
Consulting or Advisory Role - Amgen; AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Lilly Japan; MSD; Novartis; Ono Pharmaceutical; Takeda; Thermo Fisher Scientific
Research Funding - Abbvie (Inst); Amgen (Inst); Asahi Kasei (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb Japan (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Janssen (Inst); Lilly (Inst); MSD (Inst); Nihonkayaku (Inst); Novartis (Inst); Sanofi (Inst); Shionogi (Inst); Taiho Pharmaceutical (Inst); Tosoh Corporation (Inst); Tsumura & Co. (Inst)